找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Dose-Finding Designs for Early-Phase Cancer Clinical Trials; A Brief Guidebook to Takashi Daimon,Akihiro Hirakawa,Shigeyuki Matsui Book 201

[复制链接]
查看: 9371|回复: 40
发表于 2025-3-21 16:35:02 | 显示全部楼层 |阅读模式
书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials
副标题A Brief Guidebook to
编辑Takashi Daimon,Akihiro Hirakawa,Shigeyuki Matsui
视频video
概述Serves as an excellent resource in the design and analysis of early phase dose-finding trials.Covers a wide range of various methods for designing early phase dose-finding clinical trials in oncology
丛书名称SpringerBriefs in Statistics
图书封面Titlebook: Dose-Finding Designs for Early-Phase Cancer Clinical Trials; A Brief Guidebook to Takashi Daimon,Akihiro Hirakawa,Shigeyuki Matsui Book 201
描述This book provides a comprehensive introduction to statistical methods for designing early phase dose-finding clinical trials. It will serve as a textbook or handbook for graduate students and practitioners in biostatistics and clinical investigators who are involved in designing, conducting, monitoring, and analyzing dose-finding trials. The book will also provide an overview of advanced topics and discussions in this field for the benefit of researchers in biostatistics and statistical science. Beginning with backgrounds and fundamental notions on dose finding in early phase clinical trials, the book then provides traditional and recent dose-finding designs of phase I trials for, e.g., cytotoxic agents in oncology, to evaluate toxicity outcome. Included are rule-based and model-based designs, such as 3 + 3 designs, accelerated titration designs, toxicity probability interval designs, continual reassessment method and related designs, and escalation overdose control designs. This bookalso covers more complex and updated dose-finding designs of phase I-II and I/II trials for cytotoxic agents, and cytostatic agents, focusing on both toxicity and efficacy outcomes, such as designs wi
出版日期Book 2019
关键词Adaptive Design; Cancer; Dose Finding; Phase I; Phase I/II
版次1
doihttps://doi.org/10.1007/978-4-431-55585-8
isbn_softcover978-4-431-55584-1
isbn_ebook978-4-431-55585-8Series ISSN 2191-544X Series E-ISSN 2191-5458
issn_series 2191-544X
copyrightThe Author(s), under exclusive licence to Springer Japan KK 2019
The information of publication is updating

书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials影响因子(影响力)




书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials影响因子(影响力)学科排名




书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials网络公开度




书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials网络公开度学科排名




书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials被引频次




书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials被引频次学科排名




书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials年度引用




书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials年度引用学科排名




书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials读者反馈




书目名称Dose-Finding Designs for Early-Phase Cancer Clinical Trials读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 23:29:49 | 显示全部楼层
Model-Based Designs Considering Toxicity Alone,oses, and originate from the continual reassessment method (CRM). The present chapter provides a detailed description of the concepts, theories, properties, and advantages and disadvantages of the CRM, and also overview designs that are related to the CRM or that constitute extended versions of this method.
发表于 2025-3-22 03:18:04 | 显示全部楼层
Model-Assisted Designs Considering Toxicity Alone, before trial initiation. The model-assisted designs considering toxicity alone include, e.g., the modified toxicity probability interval (mTPI) design and its improved design (the mTPI-2 design), Bayesian optimal interval design, and keyboard design. In this chapter, we overview these designs and discuss related topics.
发表于 2025-3-22 08:00:12 | 显示全部楼层
Designs for Early-Phase Immunotherapeutic Agent Trials,ical to successful treatment. Such doses are found by considering the outcome related to the immune response in addition to the toxicity and efficacy outcomes. This chapter reviews several dose-finding designs for early-phase immunotherapy trials.
发表于 2025-3-22 11:36:25 | 显示全部楼层
发表于 2025-3-22 15:45:45 | 显示全部楼层
发表于 2025-3-22 19:22:38 | 显示全部楼层
发表于 2025-3-22 21:16:07 | 显示全部楼层
Book 2019book or handbook for graduate students and practitioners in biostatistics and clinical investigators who are involved in designing, conducting, monitoring, and analyzing dose-finding trials. The book will also provide an overview of advanced topics and discussions in this field for the benefit of re
发表于 2025-3-23 03:10:54 | 显示全部楼层
发表于 2025-3-23 06:48:09 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-28 01:05
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表